Clinical trials are a very important part of the research process. New treatments, medications and medical devices cannot be approved for use in Australia without going through clinical trials. Find out more about clinical trials.
The REDUCE study is testing whether reducing the dosage of antipsychotic medication of people recovering from their first episode of psychosis can lead to them having better recovery outcomes.
The Cannabidiol for At Risk Youth (CanARY) study is testing a potential new treatment called cannabidiol (CBD) for helping people with symptoms that might indicate risk of a psychotic disorder. CBD is a non-psychoactive treatment, meaning it does not give you a ‘high’.
SKY-D is investigating whether ketamine is an effective treatment for young people with depression.
A survey to better understand the experiences of caregivers and siblings of people who have experienced a manic episode or psychosis.